Geron expects Q4 RYTELO revenue ~$45-46M; FY 2024 opex ~$250-260M, cash ~$500M

GERON CORP

Preliminary Q4 2024 U.S. RYTELO net revenue expected $45M-$46M, first full quarter of launch.
FY 2024 operating expenses estimated ~$250M-$260M; cash, equivalents, and securities ~$500M as of Dec 31, 2024.
Estimates are preliminary, unaudited, subject to change upon completion of financial close and audit.
RYTELO (imetelstat) is Geron's approved telomerase inhibitor for lower-risk myelodysplastic syndromes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.